Parmax Pharma (BOM:540359) EV-to-FCF : (As of Apr. 09, 2025)

Parmax Pharma EV-to-FCF Chart

Parmax Pharma Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
EV-to-FCF		Get a 7-Day Free Trial					22.26	43.83	-25.09	-27.41	-9.29

Parmax Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-FCF	Get a 7-Day Free Trial															-	-9.29	-	-	-

Competitive Comparison of Parmax Pharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parmax Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Parmax Pharma's EV-to-FCF falls into.

Parmax Pharma EV-to-FCF Calculation

Parmax Pharma's EV-to-FCF for today is calculated as:

Parmax Pharma's current Enterprise Value is ₹223.9 Mil.
Parmax Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parmax Pharma  (BOM:540359) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Parmax Pharma's PE Ratio (TTM) for today is calculated as:

Parmax Pharma's share price for today is ₹44.70.
Parmax Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-5.552.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Parmax Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Parmax Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Parmax Pharma Business Description